INT33854

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 19
Total Number 19
Disease Relevance 10.55
Pain Relevance 5.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (OPA1) mitochondrion organization (OPA1) GTPase activity (OPA1)
Anatomy Link Frequency
hearts 3
eyes 1
coronary artery 1
medulla 1
OPA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Neurotransmitter 3 100.00 Very High Very High Very High
transdermal 12 99.82 Very High Very High Very High
Angina 24 99.76 Very High Very High Very High
Rostral ventrolateral medulla 4 99.68 Very High Very High Very High
headache 13 98.46 Very High Very High Very High
Migraine 12 97.44 Very High Very High Very High
Dorsal horn 1 97.00 Very High Very High Very High
Pain 2 96.72 Very High Very High Very High
Spinal cord 4 96.52 Very High Very High Very High
tolerance 8 94.60 High High
Disease Link Frequency Relevance Heat
Targeted Disruption 192 100.00 Very High Very High Very High
Low Tension Glaucoma 52 100.00 Very High Very High Very High
Cv General 3 Under Development 23 99.76 Very High Very High Very High
Retinal Vein Occlusion 77 98.54 Very High Very High Very High
Headache 19 98.46 Very High Very High Very High
Glaucoma 18 98.36 Very High Very High Very High
Heart Rate Under Development 8 97.44 Very High Very High Very High
Coronary Artery Disease 5 97.20 Very High Very High Very High
Pain 3 96.72 Very High Very High Very High
Nociception 2 94.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Visual failure was a prominent feature of their phenotypes and when initial screens for POLG1, POLG2, PEO1 and SLC25A4 were found to be negative, OPA1 sequencing was performed.
Localization (sequencing) of OPA1
1) Confidence 0.65 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.41 Pain Relevance 0.03
METHODS: Patients were recruited into 2 groups, NTG and control, according to inclusion and exclusion criteria.
Localization (recruited) of NTG
2) Confidence 0.64 Published 2010 Journal Ophthalmic Res. Section Body Doc Link 20068372 Disease Relevance 0.10 Pain Relevance 0
NTG-induced headache was quickly recognized as an important adverse event both in the industrial use of NTG, where it was used to produce dynamite, as well as in the use of NTG as drug.
Localization (use) of NTG associated with headache
3) Confidence 0.64 Published 2009 Journal Headache Section Abstract Doc Link 19267787 Disease Relevance 0.34 Pain Relevance 0.43
Patients who met both of following two eligibility criteria were recruited: (1) presence of BRVO in one eye, as diagnosed by retina specialists at our hospital; and (2) presence of NTG in the fellow eye or both eyes.
Localization (presence) of NTG in eyes associated with low tension glaucoma and retinal vein occlusion
4) Confidence 0.63 Published 2007 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2629887 Disease Relevance 2.53 Pain Relevance 0.26
Only recently, it became known that this was due to the release of nitric oxide (NO) by NTG.
Localization (release) of NTG
5) Confidence 0.60 Published 2003 Journal Pharm World Sci Section Abstract Doc Link 12964492 Disease Relevance 0.89 Pain Relevance 0.83
By adding different kinds of nonsolvents and adjusting the added amounts, membranes with different NTG release rates can be fabricated.
Localization (release) of NTG
6) Confidence 0.60 Published 1998 Journal J Control Release Section Abstract Doc Link 9685885 Disease Relevance 0.09 Pain Relevance 0.16
Thus, slow-release NTG ointment may be useful in the treatment of angina pectoris and congestive heart failure on a once-a-day basis.
Localization (release) of NTG in heart associated with heart rate under development and angina
7) Confidence 0.60 Published 1986 Journal Am. J. Cardiol. Section Abstract Doc Link 3019118 Disease Relevance 0.38 Pain Relevance 0.16
TTS NTG 40 cm2 (releasing 20 mg of NTG over 24 hours), nifedipine 20 mg SR, verapamil 120 mg SR and placebo were given once on 4 consecutive days according to a 4 X 4 latin-square design, twice replicated.
Localization (releasing) of NTG
8) Confidence 0.60 Published 1986 Journal G Ital Cardiol Section Abstract Doc Link 3104124 Disease Relevance 0.17 Pain Relevance 0.29
This study presents data that show that a new slow-release NTG ointment produces hemodynamic improvement over at least 24 hours.
Localization (release) of NTG
9) Confidence 0.60 Published 1986 Journal Am. J. Cardiol. Section Abstract Doc Link 3019118 Disease Relevance 0.28 Pain Relevance 0.09
Twenty patients with coronary artery disease were tested with serial gated equilibrium radionuclide ventriculography before and at various stages of continuous, once-a-day use of slow-release NTG ointment and 4 days after cessation of therapy.
Localization (release) of NTG in coronary artery associated with coronary artery disease
10) Confidence 0.60 Published 1986 Journal Am. J. Cardiol. Section Abstract Doc Link 3019118 Disease Relevance 0.27 Pain Relevance 0.08
In this double-blind randomized placebo-controlled crossover study, the antianginal and anti-ischemic effect of a new transdermal system, releasing 10 mg of nitroglycerin (NTG) over 24 hours, was assessed in 19 outpatients with stable exercise-induced angina pectoris.
Localization (releasing) of NTG associated with angina and transdermal
11) Confidence 0.60 Published 1988 Journal Am. J. Cardiol. Section Abstract Doc Link 3126635 Disease Relevance 0.17 Pain Relevance 0.26
TTS NTG 40 cm2 (releasing 20 mg of NTG over 24 hours), nifedipine 20 mg SR, verapamil 120 mg SR and placebo were given once on 4 consecutive days according to a 4 X 4 latin-square design, twice replicated.
Localization (releasing) of NTG
12) Confidence 0.60 Published 1986 Journal G Ital Cardiol Section Abstract Doc Link 3104124 Disease Relevance 0.17 Pain Relevance 0.29
Appropriate dosing regimens of controlled-release formulations of isosorbide dinitrate (ISDN) and controlled-release NTG during long-term therapy have not been established.
Localization (release) of NTG
13) Confidence 0.45 Published 1994 Journal Cardiovasc Drugs Ther Section Abstract Doc Link 7848896 Disease Relevance 0.34 Pain Relevance 0.42
We assessed the effect of transdermal nitroglycerin (NTG-TTS), releasing 5 mg/24 hr, in 11 patients with chronic stable angina during a randomized, placebo-controlled, double-blind, double crossover trial of four 1-week periods.
Localization (releasing) of NTG-TTS associated with angina and transdermal
14) Confidence 0.44 Published 1984 Journal Am. Heart J. Section Abstract Doc Link 6439019 Disease Relevance 0.26 Pain Relevance 0.26
In a double-blind, within-patient, randomized, placebo-controlled, acute study, the effects at rest and on exercise capacity of two doses of a new transdermal therapeutic system (TTS), releasing respectively 10 and 20 mg of nitroglycerin (NTG) over 24 hours, were assessed in 15 outpatients with stable exercise-induced angina pectoris.
Localization (releasing) of NTG associated with angina and transdermal
15) Confidence 0.27 Published 1985 Journal Am. Heart J. Section Abstract Doc Link 3929579 Disease Relevance 0.24 Pain Relevance 0.29
To test the hypothesis that a central mechanism may play a role in the minimal reflex tachycardia noted in response to peripheral converting enzyme inhibition, we compared the effects of intravenous (i.v.) ceronapril (CER) with nitroglycerin (NTG) on neurotransmitter release in the rostral ventrolateral medulla (RVLM), using an in vivo microdialysis method in pentobarbital anaesthetized rats. 2.
Localization (release) of NTG in medulla associated with heart rate under development, rostral ventrolateral medulla and neurotransmitter
16) Confidence 0.11 Published 1994 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 7982287 Disease Relevance 0.10 Pain Relevance 0.34
We investigated the effects of intrathecally administered nitroglycerin (NTG) which releases nitric oxide in the cell.
Localization (releases) of NTG
17) Confidence 0.09 Published 1997 Journal Masui Section Abstract Doc Link 9369051 Disease Relevance 0.44 Pain Relevance 0.68
While HSF1 was present in the cytosol of the NTG hearts, obvious nuclear localization was seen in the R120G TG hearts with or without GGA treatment (Figure 3F).
Localization (localization) of NTG in hearts associated with targeted disruption
18) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2670514 Disease Relevance 1.68 Pain Relevance 0.07
While HSF1 was present in the cytosol of the NTG hearts, obvious nuclear localization was seen in the R120G TG hearts with or without GGA treatment (Figure 3F).
Localization (localization) of NTG in hearts associated with targeted disruption
19) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2670514 Disease Relevance 1.68 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox